Fri, Apr 18, 2014, 8:43 PM EDT - U.S. Markets closed for Good Friday

Recent

% | $
Quotes you view appear here for quick access.

Vasomedical Inc. Message Board

bocamp1 296 posts  |  Last Activity: 3 hours ago Member since: Oct 13, 1998
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    My bet is.....

    by betonthenews Apr 14, 2014 11:26 PM

    That's really funny. I was thinking of the stooges when I wrote that, but I didn't remember curlys exact comment. Great stuff.
    Its hard to know what the placebo effect will be in this ALS trail. Many trials have failed due to an unexpected result in the placebo arm. Its very possible here. There is no way to predict.
    Regardless, the heart muscle drug is the most promising. Amgn spending 150 million on it says it all. So, if ALS fail, we still have over 100 million in cash and the amgn drug................

  • Reply to

    NY TIMES-Treatment Costs/Docs Advice 1

    by bocamp1 4 hours ago

    "The cardio societies plan for now to rely on published literature(don't we have plenty) on cost effectiveness. They plan to rate the value of treatments based on the cost per quality adjusted life year, or QALY, a method used in Britain and many health economists.
    Treatments costing less than about 50,000 a QALY would be rated as high value. while those costing more than 150,000 a QALY would be low value. We couldn't go on just ignoring costs."
    Ok, so what is EECP's QALY? Does Vaso even know what a QALY is? Maybe we need to hire a Health Economist.
    Sentiments in the cardio world are changing. We need a focused, domestic strategy to understand and work the new system to our advantage. It all there, can management get it done?? So far, it doesn't seem so.

  • Very insightful article on the front page today on the new changing attitude of doctors to now give much thought to the cost of a treatment before recommendations. They talk with many areas of medicine on this, but the most progressive stand here seems to be coming from the Cardio community. "The ACC and American Heart Association recently announced that they would begin to use cost data to rate the value of treatments in their joint clinical practice guidelines and performance standards."
    Costs are being integrated into all aspects of medicine now. Vaso has a great study on the cost effectiveness of eecp as it pertains to readmission rates in hospitals. And while CMS is not supposed to consider cost effectiveness in coverage decisions, private insurance companies do do a cost analysis. That is why RIOS(an x unitedhealthcare guy) was supposed to get us coverage there. But he failed that initiative from years ago, but the attention to cost is even greater now. And, we have the re admission study we didn't have before. So, why cant we get private insurance coverage.?? Are we even working on this?

  • bocamp1 by bocamp1 Apr 17, 2014 6:55 PM Flag

    SEC Mandate:
    In addition to filing annual reports on Form 10-K and quarterly reports on Form 10-Q, public companies must report certain material corporate events on a more current basis. Form 8-K is the “current report” companies must file with the SEC to announce major events that shareholders should know about.

    The recent deal, that has few specifics, certainly qualifies for an 8-k. Company has 4 days to file from deal announcement.

  • bocamp1 by bocamp1 Apr 17, 2014 6:04 PM Flag

    Ge Medical division down 2%. Ma says we Will return to profitability this year. What a CEO says, matters. Credibility matters.
    Shareholders will hold him to that statement.

    Ma is obviously in China(although PR firm refused to tell me so after many e mails asking. They want to keep his travel schedule secret) He is cutting deals with the competition that no one but he understands. Details are vague at best. Transparency is a HUGE problem at vaso and will be a major topic for the shareholder group.

  • Reply to

    My bet is.....

    by betonthenews Apr 14, 2014 11:26 PM
    bocamp1 bocamp1 Apr 17, 2014 5:55 PM Flag

    What don't you knuckleheads understand? Data on ALS trail data will be presented on the 29th at 4pm. Cant be any more exact than that. Get it?

  • Reply to

    Call Action

    by bocamp1 Apr 16, 2014 11:23 AM
    bocamp1 bocamp1 Apr 17, 2014 2:31 PM Flag

    Option guys lost the battle at xom at the 100 dollar level today; even with the 50k OI there.
    Here, they are about to loss the battle at 23 1/2. Big late rally into the close as option guys scramble for shares.

  • Buyer of 1300 april 10 puts. This guy is covering his short before expiration today. And he turns around and shorts 1300 of the may 7 1/2 puts at 1.6 and then uses proceeds to buy Aug 17 1/2 call at same 1.6.

    Trial results the 29th.................follow the money

  • Reply to

    Disgruntled Longs/Shareholder Meeting

    by bocamp1 Apr 15, 2014 6:03 PM
    bocamp1 bocamp1 Apr 16, 2014 9:50 PM Flag

    Every shares, and every shareholder counts........thanks

  • Reply to

    Update

    by bocamp1 Apr 16, 2014 11:34 AM
    bocamp1 bocamp1 Apr 16, 2014 5:03 PM Flag

    15 members
    Share count 9.3 million.

    If anyone really thinks we finished higher today, I got some swampland in NJ to sell ya.

  • Reply to

    cardiac

    by borialisnorialis Apr 16, 2014 3:51 PM
    bocamp1 bocamp1 Apr 16, 2014 4:52 PM Flag

    That is certainly what AMGN thinks. They have spent over a 7 year period 150 million dollars on a heart muscle drug that is being developed by their partner CYTK. They don't even own the entire indication there but have paid for all the trials and research. And only finishing P2 now.
    You would think rgrx could get some real dollars here if they could get manufacturing process fixed.

  • Reply to

    ECP/EECP Announcement

    by mjs62052 Apr 16, 2014 8:47 AM
    bocamp1 bocamp1 Apr 16, 2014 3:17 PM Flag

    Recent larger volume days, which have been lower, have not been fueled by shorts. There has been little shorting on these selloffs. This is certainly the direct opposite from the volume rally days pre Q, where shorting took up a large % of volume. This tells me some longs are so disappointed in MA that they have been, indeed, liquidating. I think that makes much sense and large short may now be a plus as he is absorbing seller.
    Cant say when seller(s) may be done, but I would think fairly soon. A buyback increase would help, but Ma seems deaf to all shareholders right now.
    A nice loud voice of displeasure at Meeting may help to change that.

  • Reply to

    Huge call volume again

    by bocamp1 Apr 16, 2014 10:28 AM
    bocamp1 bocamp1 Apr 16, 2014 11:54 AM Flag

    Good job shortie, investing in that rear view mirror. Always a winning recipe.
    Call trades say it all.

  • bocamp1 by bocamp1 Apr 16, 2014 11:34 AM Flag

    I want to thank those who have responded so far. Initial response is really good, with about 80% of 10 mil share count goal. Maybe we can do more?

  • bocamp1 by bocamp1 Apr 16, 2014 11:23 AM Flag

    Very strange action in the april 23 1/2 calls. With the shortened week, these things expire tomorrow. They have an OI of about 1300 contracts, and so far, over 3000 have been bought at a nickel. So, cant be just closing of short. These are new spec buys.
    Is there a chance of news(well results or other) that could hit tonight or tomorrow morning?

  • bocamp1 by bocamp1 Apr 16, 2014 11:08 AM Flag

    Have a 6 cent bid today. We haven't seen that in a while. I had been bidding at a nickel almost everyday, and today 4000 done there but I got none. Typical bs
    Something is about to break.

  • 1000 contract buyer of sept 5 call on offer at 1.3
    Yesterday, 3000 bought at 1.25
    Follow the money

  • News Leak?????

  • Reply to

    ECP/EECP Announcement

    by mjs62052 Apr 16, 2014 8:47 AM
    bocamp1 bocamp1 Apr 16, 2014 9:29 AM Flag

    If this helps reduce SG&A, I am all for it. This goes very much along the lines of the CC, de emphasizing eecp.
    The Chinese market has little need for the "Gold Standard" in eecp therapy when they can just sell cheap knockoff ECP units. That market is a sinkhole. Interesting other devices, which Ma is more excited about, are not part of this deal. We can see a clear strategy here/ like it or not.
    The real binary event for EECP is still in North America where the FDA and high standards matter. Getting that PMA should still be top priority.
    Also, vaso will be selling cheaper ECP units in the USA.
    What about India? Not clear on that

  • The timing of the yearly meeting is to our advantage. Its time to be proactive.

    I am willing to represent a shareholder group of investors here who feel vaso's management is not aligned with our interests; in terms of executive compensation, corporate strategy, and share price performance. If you would like me to be your voice at the meeting, text me with the # of shares you hold and your first name and last initial.
    All know my opinion here. So, if you sign on, realize that I will not speak in any 1/2 measures or PC platitudes. I will also not entertain long winded discussions from the group on what should or shouldn't be said. There is little time for that and frankly, too many voices drown the message. This I know from previous experience with such groups. Just know, my priority is shareholder value above all else.
    The goal here is to get 10 million shares. We just want to make our voice a little louder. If we cant get that, I don't see any point in going to meeting. So, if you want to make some noise, lets rumble. Text me at
    7322980875.
    I will update those involved with share count.
    bob c

VASO
0.3139-0.0261(-7.68%)Apr 17 3:58 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Weibo Corporation
NasdaqGSThu, Apr 17, 2014 4:00 PM EDT
Rayonier Inc.
NYSEThu, Apr 17, 2014 4:03 PM EDT